BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 10759666)

  • 1. A comparison of six commercial assays for total and free prostate specific antigen (PSA): the predictive value of the ratio of free to total PSA.
    Patel D; White PA; Milford Ward A
    BJU Int; 2000 Apr; 85(6):686-9. PubMed ID: 10759666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the clinical performance of equimolar- and skewed-response total prostate-specific antigen assays versus complexed and free PSA assays and their ratios in discriminating between benign prostatic hyperplasia and prostate cancer.
    Wians FH; Cheli CD; Balko JA; Bruzek DJ; Chan DW; Sokoll LJ
    Clin Chim Acta; 2002 Dec; 326(1-2):81-95. PubMed ID: 12417099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
    Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
    Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of non-alpha1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: analytical performance and diagnostic accuracy.
    Wesseling S; Stephan C; Semjonow A; Lein M; Brux B; Sinha P; Loening SA; Jung K
    Clin Chem; 2003 Jun; 49(6 Pt 1):887-94. PubMed ID: 12765984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percentage of free serum prostate-specific antigen: a new tool in the early diagnosis of prostatic cancer.
    Toubert ME; Guillet J; Chiron M; Meria P; Role C; Schlageter MH; Francois H; Borschneck C; Nivelon F; Desgrandchamps F; Rastel D; Cussenot O; Teillac P; Le Duc A; Najean Y
    Eur J Cancer; 1996 Nov; 32A(12):2088-93. PubMed ID: 9014750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
    Jung K; Elgeti U; Lein M; Brux B; Sinha P; Rudolph B; Hauptmann S; Schnorr D; Loening SA
    Clin Chem; 2000 Jan; 46(1):55-62. PubMed ID: 10620572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of free-to-total prostate specific antigen variability on the early diagnosis of prostate cancer: a comparative study of three immunoassays.
    de la Taille A; Houlgatte A; Houdelette P; Goluboff ET; Berlizot P; Ricordel I
    Br J Urol; 1998 Sep; 82(3):389-92. PubMed ID: 9772876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical utility of measuring free-to-total prostate-specific antigen (PSA) ratio and PSA density in differentiating between benign prostatic hyperplasia and prostate cancer.
    Kochañska-Dziurowicz AA; Mielniczuk MR; Stojko A; Kaletka J
    Br J Urol; 1998 Jun; 81(6):834-8. PubMed ID: 9666767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic accuracy of percent free prostate-specific antigen in prostatic pathology and its usefulness in monitoring prostatic cancer patients.
    Minardi D; Galosi AB; Recchioni A; Giammarco L; Polito M; Muzzonigro G
    Urol Int; 2001; 67(4):272-82. PubMed ID: 11741128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer.
    Okegawa T; Noda H; Nutahara K; Higashihara E
    Eur Urol; 2000 Oct; 38(4):380-7. PubMed ID: 11025374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum free prostate-specific antigen in the diagnosis of prostate cancer.
    Leung HY; Lai LC; Day J; Thomson J; Neal DE; Hamdy FC
    Br J Urol; 1997 Aug; 80(2):256-9. PubMed ID: 9284198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total PSA, free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: which is clinically effective and when?
    Basso D; Fogar P; Piva MG; Navaglia F; Mazza S; Prayer-Galetti T; Castellucci E; Pagano F; Plebani M
    Urology; 2000 May; 55(5):710-5. PubMed ID: 10792086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications.
    Jung K; Brux B; Lein M; Rudolph B; Kristiansen G; Hauptmann S; Schnorr D; Loening SA; Sinha P
    Clin Chem; 2000 Jan; 46(1):47-54. PubMed ID: 10620571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
    Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update.
    Stephan C; Klaas M; Müller C; Schnorr D; Loening SA; Jung K
    Clin Chem; 2006 Jan; 52(1):59-64. PubMed ID: 16391327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advantages of replacing the total PSA assay with the assay for PSA-alpha 1-antichymotrypsin complex for the screening and management of prostate cancer.
    Wu JT; Liu GH
    J Clin Lab Anal; 1998; 12(1):32-40. PubMed ID: 9484667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: critical analysis of two different test populations.
    Veltri RW; Miller MC
    Urology; 1999 Apr; 53(4):736-45. PubMed ID: 10197849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
    Stephan C; Stroebel G; Heinau M; Lenz A; Roemer A; Lein M; Schnorr D; Loening SA; Jung K
    Cancer; 2005 Sep; 104(5):993-1003. PubMed ID: 16007682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance and limitations of f/tPSA in differential diagnosis of prostate cancer with tPSA levels between 4 and 10 ng/ml].
    Chen ZD; Wei SM; Cai SL
    Zhonghua Wai Ke Za Zhi; 2004 May; 42(10):593-5. PubMed ID: 15265401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.